|
Synonyms: Lu AG13909 | Lu-AG13909
Compound class:
Antibody
Comment: Asedebart (Lu AG13909) is a humanized monoclonal antibody that binds (neutralizes) human ACTH (corticotropin) by acting as a ligand trap. Peptide matches for the heavy and light chains of asedebart are claimed in patent US10047157B2, and form the antibody named Ab13.H therein [1]. The antibody is intended to block ACTH-mediated activation of melanocortin receptors in the adrenal glands, as a mechanism to reduce the overproduction of cortisol and aldosterone in ACTH‑dependent conditions such as Cushing's disease/syndrome.
|
| No information available. |
Summary of Clinical Use ![]() |
| Asedebart (Lu AG13909) was progressed as a clinical candidate for the treatment of conditions that are characterised by elevated cortisol levels, such as Cushing's disease and congenital adrenal hyperplasia [2]. Asedebart has been granted orphan designations for use in these indications in Japan, the US. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05669950 | A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia | Phase 1/Phase 2 Interventional | H. Lundbeck A/S | ||
| NCT06471829 | A Trial of Lu AG13909 in Adult Participants With Cushing's Disease | Phase 2 Interventional | H. Lundbeck A/S | ||